Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Discoloration Defense is a topical skin-brightening serum developed by SkinCeuticals. It is a hydroquinone-free cosmetic formulation designed to reduce the appearance of skin discoloration, including dark spots, hyperpigmentation, and post-inflammatory discoloration. The serum contains a combination of active ingredients: 3% tranexamic acid, 1% kojic acid, 5% niacinamide (vitamin B3), and 5% HEPES (hydroxyethylpiperazine ethane sulfonic acid). These components work synergistically to target melanin production pathways and promote skin cell turnover, resulting in a more even skin tone and improved brightness. It is marketed as a cosmetic product for topical application to the face, rather than a prescription pharmaceutical drug.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Discoloration Defense.